This article is more than 5 years old. Information may no longer be current.

Eyenovia receives Notices of Allowance on two patent applications

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyenovia has received Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications providing coverage on physiologic microdroplet ejection diameters and velocities, according to a press release.

Once the new patents are issued, Eyenovia will hold eight U.S. patents and 27 issued and allowed international patents in micro-therapeutic ophthalmic delivery.

“We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye,” Sean Ianchulev, MD, MPH, Eyenovia’s CEO and chief medical officer, said in the release. “With an expanding global intellectual property portfolio, we look forward to advancing our late-stage clinical assets for mydriasis, glaucoma and myopia into phase 3 development.”